（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《關於召開2025年半年度業績說明 會的公告》。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，二零二五年八月十一日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 | | | 诺诚健华医药有限公司 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关 ...

| | | 诺诚健华医药有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 8 月 20 日(星期三)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 13 日(星期三)至 8 月 19 日(星期二)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答 诺诚健华医药有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发布公 司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度 经营成果、财务状况，公司计划于 ...

香港联交所最新资料显示，8月5日，兴证全球基金管理有限公司减持诺诚健华-B(09969)89.2639万股， 每股作价18.8587港元，总金额约为1683.40万港元。减持后最新持股数目为7467.186万股，最新持股比 例为4.99%。 ...

| 表格序號 | | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 | 佔已發行的 有關事件的日期 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | | (請參閱上述*註 | 有投票棒股 (日 / 月 / 年) | | | | | | | | 一段 | | 份百分比 | | CS20250806E00020 | 兴证全球基金管理有限公司 | 1201(L) | | 892,639(L) | HKD 18.8587 | | 74,671,860(L) | ( % ) 4.99(L)05/08/2025 | | | | ■ 诺诚健华 分时 多日 日K 周K 月K 季K 年K 1分 3分 5分 10分 15分 30分 1小时 2小时 3小时 4小时 Tick 1天:1分K v | | | | | | | | + 8 × 87 | | × × × × × × × × × × × × × △ の ○ ◎ の の ◎ の の ◎ | | | ...

Core Points - The Shanghai Composite Index closed at 3638.40 points with a change of 0.12% and a total trading volume of 1,206.179 billion yuan [1] - Eight A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stock Performance - Stock "信立泰" (Code: 002294) decreased by 1.86% with a 5-day moving average of 49.37 yuan and a 10-day moving average of 49.62 yuan, showing a distance of -0.49% [1] - Stock "万邦德" (Code: 002082) decreased by 1.36% with a 5-day moving average of 7.48 yuan and a 10-day moving average of 7.52 yuan, also showing a distance of -0.49% [1] - Stock "毕得医药" (Code: 688073) decreased by 2.96% with a 5-day moving average of 59.09 yuan and a 10-day moving average of 59.27 yuan, indicating a distance of -0.30% [1] Group 2: Additional Stocks with Moving Average Crossovers - Stock "吉贝尔" (Code: 688566) decreased by 3.58% with a 5-day moving average of 33.90 yuan and a 10-day moving average of 33.97 yuan, showing a distance of -0.20% [1] - Stock "诺诚健华" (Code: 688428) decreased by 6.03% with a 5-day moving average of 30.02 yuan and a 10-day moving average of 30.07 yuan, indicating a distance of -0.18% [1] - Stock "丽人丽妆" (Code: 605136) increased by 0.81% with a 5-day moving average of 9.82 yuan and a 10-day moving average of 9.84 yuan, showing a distance of -0.15% [1]

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.28% and a total trading volume of 878.86 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3623.70 points, reflecting a decrease of 0.28% [1] - The total trading volume in the A-share market is reported at 878.86 billion yuan [1] Group 2: Moving Averages Analysis - Seven A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xintai (002294) with a distance of -0.51% - Wanbangde (002082) with a distance of -0.45% - Haixiang Pharmaceutical (002099) with a distance of -0.24% [1] Group 3: Individual Stock Performance - Xintai (002294) is down by 2.07% with a latest price of 47.79 yuan, which is 3.66% below its 10-day moving average [1] - Wanbangde (002082) has decreased by 0.95%, trading at 7.30 yuan, 2.93% below its 10-day moving average [1] - Haixiang Pharmaceutical (002099) is down by 0.33%, with a latest price of 6.08 yuan, 1.95% below its 10-day moving average [1] - Other stocks such as Bidai Pharmaceutical (688073) and Kewah (002335) also show declines in their respective prices and moving averages [1]

Group 1 - The core point of the article is that Xingsheng Global Fund Management Co., Ltd. has reduced its stake in Nocera Health (09969.HK) by selling 892,639 shares at an average price of HKD 18.8587 per share, amounting to approximately HKD 16.83 million [1] - After the reduction, Xingsheng Global's total shareholding in Nocera Health is now 74,671,860 shares, which represents a decrease in ownership from 5.05% to 4.99% [1]

Core Viewpoint - The article highlights the emergence of 236 doubling stocks in the A-share market as of August 5, driven by active capital flow and concentrated in small and mid-cap stocks, particularly in the pharmaceutical and technology sectors [1][5]. Group 1: Doubling Stocks Performance - Among the doubling stocks, Aowei New Materials leads with a remarkable increase of over 15 times, while Shuotai Shen and *ST Yushun have risen over 5 times, and several others have seen increases exceeding 2 times [3]. - Shuotai Shen, focusing on unmet clinical needs, has gained significant attention from funds, with 49 funds holding a total market value of 1.228 billion yuan by the end of Q2 [3]. - Victory Technology has also benefited from the AI-driven demand for high-end products, with a 90% increase in Q1 and a high fund holding ratio of 14.48% [4]. Group 2: Fund Strategies and Market Dynamics - The active trading environment has led to a preference for small-cap stocks, which can achieve significant price increases with relatively small capital [5]. - The funds that have capitalized on the doubling trend are primarily small and mid-cap strategy funds, with notable performances from medical and technology-themed funds [6]. - The pharmaceutical sector, particularly innovative drug companies, is expected to see long-term investment value supported by industry growth and enhanced R&D capabilities [7]. Group 3: Future Outlook - The innovative drug sector is anticipated to continue its upward trajectory, with increasing collaboration and licensing deals expected to drive growth [7]. - The human-robotics sector is also highlighted for its potential, with advancements in technology and materials expected to create investment opportunities [7].

Group 1 - The core viewpoint of the news is that the CSI Hong Kong 300 Biopharmaceutical Index has shown significant growth, with a 24.33% increase over the past month, a 60.33% increase over the past three months, and a remarkable 137.42% increase year-to-date [1] - The CSI Hong Kong 300 Industry Index series is categorized according to the China Securities Index industry classification standards, reflecting the overall performance of different industries in the Hong Kong market [1] - The CSI Hong Kong 300 Biopharmaceutical Index is composed entirely of securities from the Hong Kong Stock Exchange, with 100% of its holdings in the biopharmaceutical sector [1] Group 2 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, but can be modified in the event of temporary adjustments due to changes in the underlying index samples [2] - Special events affecting sample companies, such as delisting or mergers, will lead to corresponding adjustments in the CSI Hong Kong 300 Industry Index series [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 5 ...